Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients with Estrogen Receptor (Er)-Positive, Human Epidermal Growth Factor Receptor Type 2 (Her2)-Negative Breast Cancer-Anett.
Journal of Clinical Oncology（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined